{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:12:08Z","timestamp":1779088328033,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40256-023-00600-w","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T15:05:33Z","timestamp":1690988733000},"page":"533-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Yinxue","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingyu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"600_CR1","doi-asserted-by":"crossref","unstructured":"Hoerger TJ, Simpson SA, Yarnoff BO, et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. Am J Kidney Dis.\u00a02015;65(3):40311.","DOI":"10.1053\/j.ajkd.2014.09.023"},{"key":"600_CR2","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. US Department of Health and Human Services, Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/2019-nationalfacts.html. Accessed 12 Aug 2019."},{"key":"600_CR3","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u20131858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"issue":"8","key":"600_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4103\/0366-6999.204103","volume":"130","author":"K-K Song","year":"2017","unstructured":"Song K-K, Zhao D-L, Wang Y-D, et al. Analysis of factors associated with death in maintenance hemodialysis patients: a multicenter study in China. Chin Med J (Engl). 2017;130(8):885\u201391.","journal-title":"Chin Med J (Engl)"},{"key":"600_CR5","doi-asserted-by":"crossref","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296\u2013305.","DOI":"10.1056\/NEJMoa041031"},{"key":"600_CR6","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1111\/j.1523-1755.2005.09906.x","volume":"99","author":"J Fort","year":"2005","unstructured":"Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl. 2005;99:S25\u20139 (MEDLINE: 16336573).","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"600_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ihj.2022.08.004","volume":"74","author":"A Shrivastava","year":"2022","unstructured":"Shrivastava A, Nath RK, Mahapatra HS, et al. Ultra-low CONtraSt PCI vs conVEntional PCI in patients of ACS with increased risk of CI-AKI (CONSaVE-AKI). Indian Heart J. 2022;74(5):363\u20138.","journal-title":"Indian Heart J"},{"issue":"4","key":"600_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"D Giacoppo","year":"2021","unstructured":"Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2021;42(4):308\u201319.","journal-title":"Eur Heart J"},{"issue":"3","key":"600_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/0003319709344574","volume":"61","author":"A El-Menyar","year":"2010","unstructured":"El-Menyar A, Hussein H, Suwaidi JA. Coronary stent thrombosis in patients with chronic renal insufficiency. Angiology. 2010;61(3):297\u2013303.","journal-title":"Angiology"},{"issue":"4","key":"600_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2215\/CJN.06790712","volume":"8","author":"N Jain","year":"2013","unstructured":"Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol. 2013;8(4):665\u201374.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"600_CR11","doi-asserted-by":"publisher","first-page":"e001683","DOI":"10.1161\/CIRCINTERVENTIONS.115.001683","volume":"8","author":"U Baber","year":"2015","unstructured":"Baber U, Mehran R, Kirtane AJ, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015;8(6):e001683.","journal-title":"Circ Cardiovasc Interv"},{"key":"600_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/5584_2016_109","volume":"906","author":"FS Sharif-Askari","year":"2017","unstructured":"Sharif-Askari FS, Sulaiman SAS, Sharif-Askari NS. Anticoagulation therapy in patients with chronic kidney disease. Adv Exp Med Biol. 2017;906:101\u201314.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"600_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2174\/157489010793351908","volume":"5","author":"GI Tagarakis","year":"2010","unstructured":"Tagarakis GI. Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents. Recent Pat Cardiovasc Drug Discov. 2010;5(3):208\u201311.","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"600_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijcard.2021.07.047","volume":"342","author":"MR Jacobsen","year":"2021","unstructured":"Jacobsen MR, Engstr\u00f8m T, Torp-Pedersen C, et al. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction. Int J Cardiol. 2021;342:15\u201322.","journal-title":"Int J Cardiol"},{"issue":"2022","key":"600_CR15","first-page":"6476777","volume":"31","author":"Y Chen","year":"2022","unstructured":"Chen Y, Shaowen Tu, Chen Z, et al. Ticagrelor versus clopidogrel in patients with severe renal insufficiency undergoing PCI for acute coronary syndrome. J Interv Cardiol. 2022;31(2022):6476777.","journal-title":"J Interv Cardiol"},{"issue":"9","key":"600_CR16","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1016\/j.ekir.2021.06.031","volume":"6","author":"N Jain","year":"2021","unstructured":"Jain N, Phadnis MA, Hunt SL, et al. Comparative effectiveness and safety of oral p2y12 inhibitors in patients on chronic dialysis. Kidney Int Rep. 2021;6(9):2381\u201391.","journal-title":"Kidney Int Rep."},{"issue":"11","key":"600_CR17","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056\u201367.","journal-title":"Circulation"},{"issue":"3","key":"600_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40256-018-00318-0","volume":"19","author":"C-H Lee","year":"2019","unstructured":"Lee C-H, Tsai T-H, Lin C-J, Hsueh S-K, Chung W-J, Cheng C-I. Efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease with acute myocardial infarction. Am J Cardiovasc Drugs. 2019;19(3):325\u201334.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"600_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/bcp.14935","volume":"88","author":"Y-S Li","year":"2022","unstructured":"Li Y-S, Wang S-H, Hwang S-J, Yang Y-H, Hsieh K-P. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Br J Clin Pharmacol. 2022;88(1):145\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"600_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2215\/CJN.12120720","volume":"16","author":"TA Mavrakanas","year":"2021","unstructured":"Mavrakanas TA, Kamal O, Charytan DM. Prasugrel and ticagrelor in patients with drug-eluting stents and kidney failure. Clin J Am Soc Nephrol. 2021;16(5):757\u201364.","journal-title":"Clin J Am Soc Nephrol"},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"707722","DOI":"10.3389\/fcvm.2021.707722","volume":"8","author":"JW Roh","year":"2022","unstructured":"Roh JW, Lee S-J, Kim B-K, et al. Ticagrelor vs clopidogrel in acute coronary syndrome patients with chronic kidney disease after new-generation drug-eluting stent implantation. Front Cardiovasc Med. 2022;8:707722.","journal-title":"Front Cardiovasc Med."},{"issue":"18","key":"600_CR22","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.jacc.2014.01.069","volume":"63","author":"WJ Kikkert","year":"2014","unstructured":"Kikkert WJ, van Geloven N, van der Laan MH, et al. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol. 2014;63(18):1866\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"600_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"600_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"600_CR25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"3","key":"600_CR26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1055\/s-0040-1708841","volume":"46","author":"J Lutz","year":"2020","unstructured":"Lutz J, Jurk RNK. Platelets in advanced chronic kidney disease: two sides of the coin. Semin Thromb Hemost. 2020;46(3):342\u201356.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"600_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12882-019-1499-3","volume":"20","author":"S Xiaole","year":"2019","unstructured":"Xiaole S, Yan B, Wang L, Lv J, Cheng H, Chen Y. Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2019;20(1):309.","journal-title":"BMC Nephrol"},{"key":"600_CR28","doi-asserted-by":"publisher","first-page":"107143","DOI":"10.1016\/j.vph.2023.107143","volume":"148","author":"N Jain","year":"2023","unstructured":"Jain N, Corken A, Arthur JM, et al. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascul Pharmacol. 2023;148:107143.","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"600_CR29","doi-asserted-by":"publisher","first-page":"20826","DOI":"10.1038\/s41598-021-00360-0","volume":"11","author":"Y-C Tung","year":"2021","unstructured":"Tung Y-C, Chang C-J, Liu J-R, Chang S-H, Chan Y-H, Kuo C-T, See L-C. Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study. Sci Rep. 2021;11(1):20826.","journal-title":"Sci Rep"},{"issue":"3","key":"600_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2217\/cer-2017-0074","volume":"7","author":"B Wu","year":"2018","unstructured":"Wu B, Lin H, Tobe RG, Zhang L, He B. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. J Comp Eff Res. 2018;7(3):281\u201391.","journal-title":"J Comp Eff Res."},{"issue":"23","key":"600_CR31","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","volume":"140","author":"D-W Park","year":"2019","unstructured":"Park D-W, Kwon O, Jang J-S, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019;140(23):1865\u201377.","journal-title":"Circulation"},{"key":"600_CR32","doi-asserted-by":"crossref","unstructured":"Kang H-J, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2015;169(6):899\u2013905.e1.","DOI":"10.1016\/j.ahj.2015.03.015"},{"key":"600_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2019.09.011","volume":"290","author":"Y Sun","year":"2019","unstructured":"Sun Y, Li C, Zhang L, et al. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients. Atherosclerosis. 2019;290:52\u20138.","journal-title":"Atherosclerosis"},{"issue":"6","key":"600_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","volume":"156","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Micco LD, Razavian M, Craig JC, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445\u201359.","journal-title":"Ann Intern Med"},{"issue":"7","key":"600_CR35","doi-asserted-by":"publisher","first-page":"e019630","DOI":"10.1161\/JAHA.120.019630","volume":"10","author":"JY Cho","year":"2021","unstructured":"Cho JY, Lee S-Y, Yun KH, et al. Factors related to major bleeding after ticagrelor therapy: results from the TICO trial. J Am Heart Assoc. 2021;10(7):e019630.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"600_CR36","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00380-022-02029-8","volume":"37","author":"CA Graham","year":"2022","unstructured":"Graham CA, Tan MK, Chew DP, et al. Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Heart Vessels. 2022;37(8):1291\u20138.","journal-title":"Heart Vessels"},{"issue":"2","key":"600_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11739-020-02404-1","volume":"16","author":"F Gragnano","year":"2021","unstructured":"Gragnano F, Moscarella E, Calabro P, et al. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Intern Emerg Med. 2021;16(2):379\u201387.","journal-title":"Intern Emerg Med"},{"key":"600_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.thromres.2022.04.004","volume":"216","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang Na, Suo M, et al. In-hospital outcomes of ticagrelor versus clopidogrel in high bleeding risk patients with acute coronary syndrome: findings from the CCC-ACS project. Thromb Res. 2022;216:43\u201351.","journal-title":"Thromb Res"},{"issue":"17","key":"600_CR39","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.4103\/0366-6999.239306","volume":"131","author":"H-Y Wang","year":"2018","unstructured":"Wang H-Y, Li Yi, Xiao-Ming Xu, et al. Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chin Med J (Engl). 2018;131(17):2017\u201324.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"600_CR40","doi-asserted-by":"publisher","first-page":"e000989","DOI":"10.1161\/JAHA.114.000989","volume":"3","author":"AG Mainous","year":"2014","unstructured":"Mainous AG, Tanner RJ, Shorr RI, Limacher MC. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011\u20132012. J Am Heart Assoc. 2014;3(4):e000989.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"600_CR41","first-page":"183","volume":"28","author":"M Stuntz","year":"2016","unstructured":"Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012\u20132015. Prev Med Rep. 2016;28(5):183\u20136.","journal-title":"Prev Med Rep."}],"updated-by":[{"DOI":"10.1007\/s40256-023-00607-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000}}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00600-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:28:08Z","timestamp":1693214888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00600-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00600-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40256-023-00607-3","asserted-by":"object"}]},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"19 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40256-023-00607-3","URL":"https:\/\/doi.org\/10.1007\/s40256-023-00607-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors Yinxue Guo, Pingyu Ge, Ziju Li, Jingxia Xiao and Lirui Xie declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This meta-analysis is based on previously published studies and does not contain any studies with human participants or animals performed by any of the authors. Therefore, no ethical approval was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All data generated or analyzed during this study are included in this published article. References have been provided. The full text articles containing those data can be obtained from electronic databases including PubMed, EMBASE, Web of Science and so on.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Yinxue Guo, Pingyu Ge, Ziju Li, Jingxia Xiao, and Lirui Xie were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. Yinxue Guo and Pingyu Ge wrote the final draft. All the authors approved the final manuscript as it has been written.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}